Genes differentially expressed in CD34+ cells from patients with low-risk and high-risk MDS
| Gene . | Accession . | Map . | Description . | -fold . |
|---|---|---|---|---|
| Down-regulation | ||||
| ADPRF | U52521 | — | Arfaptin (ADP-ribosylation factor) | 8 |
| ARD1 | U14575 | 1 | Activator of RNA decay 1 | 5 |
| ARHH | Z35227 | 4p13 | Ras homolog gene family H | 6 |
| CDH | D88797 | 5q31 | Cadherin | 6 |
| CRA | U78556 | 1 | Cisplatin resistance associated | >10 |
| DLEC1 | AB020522 | 3p22 | Deleted in lung and esophageal cancer | >10 |
| DYRK2 | Y09216 | 12 | Dual tyrosine-phosphorylation-regulated kinase 2 | 6 |
| H-PLK | M55422 | 7 | Krueppel-related zinc finger protein | 8 |
| IFNAR1 | J03171 | 21q22.1 | Interferon alpha receptor 1 | >10 |
| LCP2 | U20158 | 5q33.1 | Lymphocyte cytosolic protein | 7 |
| MNDA | M81750 | 1q22 | Myeloid cell nuclear differentiation antigen | 7 |
| NFE2 | S77763 | 12q13 | Nuclear factor, erythroid derived 2 | 8 |
| NKG7 | S69115 | 19 | Natural killer cell group 7 | 5 |
| P63 | Y16961 | 3q27-q29 | Tumor protein 63 | 7 |
| PAGE1 | AF058989 | X | Prostate-associated gene 1 | 6 |
| PF4 | M25897 | 4q12-q21 | Platelet factor 4 | 10 |
| PIK3CG | X83368 | 7 | Phosphatidylinositol kinase 3 catalytic gamma | >10 |
| PRKAA1 | AB022017 | 5p12 | AMP-activated protein kinase alpha 1 | 8 |
| RGS19 | X91809 | — | Regulator of G-protein signaling 19 | 7 |
| SDF1 | L36033 | 10q11.1 | Stromal-cell-derived factor 1 | >10 |
| STAT2 | U18671 | 12 | Signal transducer and activator of transcription 2 | >10 |
| TDGF3 | M96956 | Xq21-q22 | Teratocarcinoma-derived growth factor 3 | 5 |
| UPK3 | AF085808 | 22q13.31 | Uroplakin | >10 |
| Up-regulation | ||||
| ALTE | D31762 | 6p21 | AC-like transposable element | 6 |
| BENE | U17077 | 2q13 | T-lymphocyte maturation factor | >10 |
| CCND1 | M73554 | 11q13 | Cyclin D1 | >10 |
| CD9 | M38690 | 12q13 | CD9 antigen | 6 |
| CDK2AP1 | AF089814 | 11q13 | CDK2-associated protein | 10 |
| GA733-2 | M93036 | 4q | Carcinoma-associated antigen | >10 |
| HRAS1 | J00277 | 11p15.5 | H-RAS 1 | 6 |
| IEX1 | S81914 | 6p21.3 | Radiation-inducible immediate-early response gene | 9 |
| JUND | X56681 | 19p13.2 | Jun-D proto-oncogene | 5 |
| MAGE1 | M77481 | Xq28 | Melanoma antigen 1 | >10 |
| MAGE3 | U03735 | Xq28 | Melanoma antigen 3 | 7 |
| MAGE6 | U10691 | Xq28 | Melanoma antigen 6 | >10 |
| MIG2 | Z24725 | 14 | Mitogen-inducible gene | 8 |
| MKPL | AF038844 | 17q12 | MKP1-like protein tyrosine phosphatase | 6 |
| MLF2 | AF070539 | 12p13 | Myeloid leukemia factor 2 | 8 |
| NCOR1 | AF044209 | 17p11.2 | Nuclear receptor corepressor 1 | 7 |
| AB000584 | 19p | Prostate-derived factor | >10 | |
| PSMD11 | AB003102 | 17 | Proteasome 26S subunit p44.5 | 5 |
| PTPRN | L18983 | 2q35 | Protein tyrosine phosphatase receptor N | 5 |
| RAI3 | AF095448 | 12p13 | Retinoic-acid-induced gene | 8 |
| STIP1 | M86752 | 11q13 | Stress-induced phosphoprotein 1 | >10 |
| TK1 | M15205 | 17q23 | Thymidine kinase 1 | 5 |
| TM4SF3 | M35252 | 12 | Transmembrane 4 superfamily 3 | >10 |
| TOM1 | AJ006973 | 22q13.1 | Target of myb 1 | 5 |
| Gene . | Accession . | Map . | Description . | -fold . |
|---|---|---|---|---|
| Down-regulation | ||||
| ADPRF | U52521 | — | Arfaptin (ADP-ribosylation factor) | 8 |
| ARD1 | U14575 | 1 | Activator of RNA decay 1 | 5 |
| ARHH | Z35227 | 4p13 | Ras homolog gene family H | 6 |
| CDH | D88797 | 5q31 | Cadherin | 6 |
| CRA | U78556 | 1 | Cisplatin resistance associated | >10 |
| DLEC1 | AB020522 | 3p22 | Deleted in lung and esophageal cancer | >10 |
| DYRK2 | Y09216 | 12 | Dual tyrosine-phosphorylation-regulated kinase 2 | 6 |
| H-PLK | M55422 | 7 | Krueppel-related zinc finger protein | 8 |
| IFNAR1 | J03171 | 21q22.1 | Interferon alpha receptor 1 | >10 |
| LCP2 | U20158 | 5q33.1 | Lymphocyte cytosolic protein | 7 |
| MNDA | M81750 | 1q22 | Myeloid cell nuclear differentiation antigen | 7 |
| NFE2 | S77763 | 12q13 | Nuclear factor, erythroid derived 2 | 8 |
| NKG7 | S69115 | 19 | Natural killer cell group 7 | 5 |
| P63 | Y16961 | 3q27-q29 | Tumor protein 63 | 7 |
| PAGE1 | AF058989 | X | Prostate-associated gene 1 | 6 |
| PF4 | M25897 | 4q12-q21 | Platelet factor 4 | 10 |
| PIK3CG | X83368 | 7 | Phosphatidylinositol kinase 3 catalytic gamma | >10 |
| PRKAA1 | AB022017 | 5p12 | AMP-activated protein kinase alpha 1 | 8 |
| RGS19 | X91809 | — | Regulator of G-protein signaling 19 | 7 |
| SDF1 | L36033 | 10q11.1 | Stromal-cell-derived factor 1 | >10 |
| STAT2 | U18671 | 12 | Signal transducer and activator of transcription 2 | >10 |
| TDGF3 | M96956 | Xq21-q22 | Teratocarcinoma-derived growth factor 3 | 5 |
| UPK3 | AF085808 | 22q13.31 | Uroplakin | >10 |
| Up-regulation | ||||
| ALTE | D31762 | 6p21 | AC-like transposable element | 6 |
| BENE | U17077 | 2q13 | T-lymphocyte maturation factor | >10 |
| CCND1 | M73554 | 11q13 | Cyclin D1 | >10 |
| CD9 | M38690 | 12q13 | CD9 antigen | 6 |
| CDK2AP1 | AF089814 | 11q13 | CDK2-associated protein | 10 |
| GA733-2 | M93036 | 4q | Carcinoma-associated antigen | >10 |
| HRAS1 | J00277 | 11p15.5 | H-RAS 1 | 6 |
| IEX1 | S81914 | 6p21.3 | Radiation-inducible immediate-early response gene | 9 |
| JUND | X56681 | 19p13.2 | Jun-D proto-oncogene | 5 |
| MAGE1 | M77481 | Xq28 | Melanoma antigen 1 | >10 |
| MAGE3 | U03735 | Xq28 | Melanoma antigen 3 | 7 |
| MAGE6 | U10691 | Xq28 | Melanoma antigen 6 | >10 |
| MIG2 | Z24725 | 14 | Mitogen-inducible gene | 8 |
| MKPL | AF038844 | 17q12 | MKP1-like protein tyrosine phosphatase | 6 |
| MLF2 | AF070539 | 12p13 | Myeloid leukemia factor 2 | 8 |
| NCOR1 | AF044209 | 17p11.2 | Nuclear receptor corepressor 1 | 7 |
| AB000584 | 19p | Prostate-derived factor | >10 | |
| PSMD11 | AB003102 | 17 | Proteasome 26S subunit p44.5 | 5 |
| PTPRN | L18983 | 2q35 | Protein tyrosine phosphatase receptor N | 5 |
| RAI3 | AF095448 | 12p13 | Retinoic-acid-induced gene | 8 |
| STIP1 | M86752 | 11q13 | Stress-induced phosphoprotein 1 | >10 |
| TK1 | M15205 | 17q23 | Thymidine kinase 1 | 5 |
| TM4SF3 | M35252 | 12 | Transmembrane 4 superfamily 3 | >10 |
| TOM1 | AJ006973 | 22q13.1 | Target of myb 1 | 5 |
These genes were selected because a greater than 5-fold difference in expression occurred in CD34+ cells from marrow samples in patients with low-risk compared with high-risk MDS.
Abbreviations are explained in Table 2.